RespireRx Pharmaceuticals Inc. RSPI
Set alert
0.00 USD 0.00 0.00%
At close · Dec 15
0.0014 Day range 0.0018
0.0001 52-week range 0.0027
- YTD
- 0.00%
- 1 year
- +125.00%
- Open
- 0.0014
- Prev close
- 0.0018
- Mkt cap
- 657.75K
- Vol
- 200
- Avg vol
- 30.10K
- EPS
- -0.02
- P/E
- -0.09
More statistics
- Low
- 0.0014
- High
- 0.0018
- Earnings
- Apr 17, 2023
Next earnings
Apr 17, 2023
Expected Apr 17, 2023. Consensus EPS estimate 0.00.
Financials — quick view
RSPI Revenue — quarterly 0
RSPI Net income — quarterly -860.16K
RSPI EPS — quarterly -0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 21, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| May 22, 2023 | Mar 1, 2023 | 0.00 | -0.01 | — | — |
| Apr 17, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 17, 2022 | Sep 1, 2022 | 0.00 | -0.01 | — | — |
| Aug 22, 2022 | Jun 1, 2022 | 0.00 | -0.01 | — | — |
News
- Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK)
- RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
- RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement
- RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
- RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
- RespireRx's key asset moves to next stage of NIH initiative
- RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
- RespireRx Pharmaceuticals strengthens board, adding new director
- RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
- RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81
Your note
Sign in to keep a note on RSPI — it syncs with the Stock Master app.